BROADWOOD PARTNERS, L.P.

USReporting entityDirector2 companies · 24mo

Transactions

Issuers

Buys / Sells

66/12

Last tx

27 Apr 2026

Behaviour

3 purchases reported after at least 12 months of silence — most recent on 16 Apr 2026.

Current positions

Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.

Issuer	Shares	Source	Last tx	Detail
Lineage Cell Therapeutics, Inc.	41,666,255	reported	06 Feb 2024	tx 6+9,102,992
STAAR SURGICAL CO	13,320,675	reported	07 Apr 2025	tx 46+1,316,818−511,954
Insight Molecular Diagnostics Inc.	12,684,884	reported	27 Apr 2026	tx 40+51,326,686.35−1,149,863.18
Asterias Biotherapeutics, Inc.	5,292,156	reported	16 Oct 2017	tx 2+1,592,308

Track record

Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 54 buys in history.

1 month

+19.5%

Sample54

Win rate (≥5%)63%

Hit rate (>0)70%

3 months

+5.8%

Sample42

Win rate (≥5%)52%

Hit rate (>0)67%

6 months

+45.6%

Sample42

Recent transactions

Date	Type	Issuer	Qty	Price
23 Apr 2026	PURCHASE	Insight Molecular Diagnostics Inc.	280,381	3.50 USD
23 Apr 2026	PURCHASE	Insight Molecular Diagnostics Inc.	0	0.00 USD
24 Apr 2026	PURCHASE	Insight Molecular Diagnostics Inc.	38,880	3.53 USD
24 Apr 2026	PURCHASE	Insight Molecular Diagnostics Inc.	0	0.00 USD
27 Apr 2026	PURCHASE	Insight Molecular Diagnostics Inc.	250,923

InsiderLens aggregates public information issued by financial regulators (SEC, AMF, FCA, BaFin, AFM, FI, HKEX, ASX). The service constitutes neither investment advice nor a recommendation to buy or sell. Past performance is no guarantee of future results. Investing in financial instruments carries the risk of capital loss.

Current positions

Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.

Issuer	Shares	Source	Last tx	Detail
Lineage Cell Therapeutics, Inc.	41,666,255	reported	06 Feb 2024	tx 6+9,102,992
STAAR SURGICAL CO	13,320,675	reported	07 Apr 2025	tx 46+1,316,818−511,954
Insight Molecular Diagnostics Inc.	12,684,884	reported	27 Apr 2026	tx 40+51,326,686.35−1,149,863.18
Asterias Biotherapeutics, Inc.	5,292,156	reported	16 Oct 2017	tx 2+1,592,308

Track record

Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 54 buys in history.

1 month

+19.5%

Sample54

Win rate (≥5%)63%

Hit rate (>0)70%

3 months

+5.8%

Sample42

Win rate (≥5%)52%

Hit rate (>0)67%

6 months

+45.6%

Sample42

Recent transactions

Date	Type	Issuer	Qty	Price
23 Apr 2026	PURCHASE	Insight Molecular Diagnostics Inc.	280,381	3.50 USD
23 Apr 2026	PURCHASE	Insight Molecular Diagnostics Inc.	0	0.00 USD
24 Apr 2026	PURCHASE	Insight Molecular Diagnostics Inc.	38,880	3.53 USD
24 Apr 2026	PURCHASE	Insight Molecular Diagnostics Inc.	0	0.00 USD
27 Apr 2026	PURCHASE	Insight Molecular Diagnostics Inc.	250,923